Trial · NCT04654351
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE) | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants With Injection Site Reactions | TAK-667 10-30 mg | 2 | percentage of participants | ||
| Number of Participants Who Experienced at Least One TEAE Related to Resting 12-lead Electrocardiogram | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants Who Experienced at Least One TEAE Related to Vital Sign | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants Who Experienced at Least One TEAE Related to Clinical Laboratory Parameters | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants Who Experience at Least One TEAE Related to Clinically Significant Changes in Reproductive Hormones | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants Who Reported Presence of Anti-icatibant Antibodies | TAK-667 10-30 mg | 0 | Participants | ||
| Time to Onset of Symptom Relief With Investigator-Rated Symptom Scores Assessed by Investigator | TAK-667 10-30 mg | NA | Full Range 0.9 to 1.0 | hours | |
| Time to Onset of Symptom Relief With Faces Pain Scale-Revised (FPS-R) Scores for Participants of 4 Years Age and Older | TAK-667 10-30 mg | NA | Full Range 0.9 to 1.0 | hours | |
| Number of Participants Who Were Treated With Rescue Medication During Study | TAK-667 10-30 mg | 0 | Participants | ||
| Number of Participants With Worsened Intensity of Clinical HAE Symptoms Between 2 and 4 Hours After Treatment With SC Icatibant Using Investigator-Rated Symptom Scores | TAK-667 10-30 mg | 0 | Participants | ||
| Time to Initial Symptom Improvement Reported by Investigator | TAK-667 10-30 mg | NA | Full Range 0.3 to 1.0 | hours | |
| Time to Initial Symptom Improvement Reported by Participant | TAK-667 10-30 mg | NA | Full Range 0.3 to 1.0 | hours | |
| Plasma Concentration for TAK-667 | TAK-667 10-30 mg | Baseline (pre-dose) | 0 | Full Range 0 to 0 | ug/l |
| Plasma Concentration for TAK-667 | TAK-667 10-30 mg | 0.5 hours postdose | NA | Full Range 962 to 978 | ug/l |
| Plasma Concentration for TAK-667 | TAK-667 10-30 mg | 1 hour postdose | NA | Full Range 856 to 882 | ug/l |
| Plasma Concentration for TAK-667 | TAK-667 10-30 mg | 2 hours postdose | NA | Full Range 401 to 410 | ug/l |
| Plasma Concentration for TAK-667 | TAK-667 10-30 mg | 4 hours postdose | NA | Full Range 38.8 to 68.9 | ug/l |
| Plasma Concentration for TAK-667 Metabolite M-I | TAK-667 10-30 mg | Baseline (pre-dose) | 0 | Full Range 0 to 0 | ug/l |
| Plasma Concentration for TAK-667 Metabolite M-I | TAK-667 10-30 mg | 0.5 hours postdose | NA | Full Range 103 to 106 | ug/l |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04654351/results